6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-ol
• 英文别名: ethyl 2-amino-5-methoxy-4-(3-(piperidin-1-yl)propoxy)benzoate；ethyl 2-amino-5-methoxy-4-(3-piperidylpropoxy)benzoate；Ethyl 2-amino-5-methoxy-4-(3-piperidin-1-ylpropoxy)benzoate
• 化学式: C₁₈H₂₈N₂O₄
• 分子量: 336.431
• InChiKey: ZDWYKJDCRQIZPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-ol 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 乙醇 、 水 、 甲苯 、 乙腈 为溶剂， 反应 48.4h， 生成 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide (L)lactate
  参考文献：
  名称：

  LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS

  摘要：

  本发明提供了一个公式(I)的化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式；制备公式(I)的化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式的合成或制造过程；以及使用该化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式，用于治疗患有或受到细胞存活、增殖和迁移相关疾病、障碍或病况的患者，包括心血管疾病（如动脉硬化和血管再狭窄）、癌症（如AML和恶性胶质瘤）、肾小球硬化、纤维化疾病和炎症。

  公开号：

  US20150133460A1

文献信息

• Nitrogen containing heterocyclic quinoline compounds
  申请人：——

  公开号：US20030004158A1

  公开（公告）日：2003-01-02

  The present invention relates to nitrogen-containing heterocyclic quinoline compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. More particularly, the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

  本发明涉及含氮杂环喹啉化合物及其药学上可接受的盐，该化合物对激酶的磷酸化具有抑制活性，从而抑制这些激酶的活性。本发明还涉及通过抑制激酶的磷酸化来抑制激酶并治疗哺乳动物的疾病状态的方法。更具体地，本发明提供了含氮杂环化合物及其药学上可接受的盐，该化合物抑制PDGF受体的磷酸化，从而阻碍异常细胞生长和游走，并提供了一种预防或治疗细胞增殖性疾病，如动脉硬化、血管再狭窄、癌症和肾小球硬化的方法。
• Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor
  作者：Julie A. Heath、Mukund M. Mehrotra、Shannon Chi、Jin-Chen Yu、Athiwat Hutchaleelaha、Stanley J. Hollenbach、Neill A. Giese、Robert M. Scarborough、Anjali Pandey

  DOI：10.1016/j.bmcl.2004.07.041

  日期：2004.10

  4-[4-(N-Substituted-thio-carbamoyl)-1-piperazinyl]-6-methoxy-7-alkoxyamino-quinazoline derivatives such as 14 (CT53986) have been identified to be potent and selective inhibitors of the phosphorylation of PDGFR. SAR-investigations are described in the arylamine segment, C-7 appendage, and the thiourea moiety. Bioisosteres of thiourea (cyanoguanidine), and of quinazoline (quinoline-3-carbonitrile) were synthesized and are compared for their in vitro inhibitory activity. PK profiles of the optimized compounds in rat, dog, and cynomolgus monkey are described. (C) 2004 Elsevier Ltd. All rights reserved.
• [EN] LACTATE SALT OF 4-(6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS<br/>[FR] SEL DE LACTATE DU (4-ISOPROPOXYPHÉNYL)-AMIDE DE L'ACIDE 4-(6-MÉTHOXY-7-(3-PIPÉRIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPÉRAZINE-1-CARBOXYLIQUE ET LES COMPOSITIONS PHARMACEUTIQUES L'INCLUANT DANS LE TRAITEMENT DU CANCER ET D'AUTRES PATHOLOGIES OU TROUBLES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010059239A3

  公开（公告）日：2010-08-05
• (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP1490362A2

  公开（公告）日：2004-12-29
• NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF
  申请人：Kanter James

  公开号：US20100240893A1

  公开（公告）日：2010-09-23

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.